Company intelligence / Profile preview

QuantuMDx Group

Newcastle upon Tyne, England, United Kingdom

Ownership: Private
Employees: ~81
Development stage: Other

Overview

QuantuMDx’s Q-POC™ platform, a portable multiplex PCR device, is CE marked and CTDA approved for SARS-CoV-2 and respiratory panel assays, delivering results in approximately 30–35 minutes at the point of care; commercial distribution has commenced in Europe and the UK[1][2][6].

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic device
Industry: Molecular Diagnostics

Partnerships

Sansure Biotech (cooperation and licensing agreement for Q-POC commercialization and assay development in China)[2]

Beyond the preview

Go deeper on QuantuMDx Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QuantuMDx Group.

Explore the full profile